A phase I study of the MEK inhibitor trametinib combined with the MDM2 inhibitor HDM201 in RAS/RAF mutant advanced colorectal cancer

RAS/RAF mutant advanced colorectal cancer (CRC) is associated with poor outcomes and limited therapeutic options. Preclinical studies suggest that combining MEK and MDM2 inhibition may yield synergistic effects. This dose-escalation, phase I study evaluated the safety of escalating doses of the MDM2 inhibitor HDM201 combined with the MEK inhibitor trametinib at a fixed dose. KRAS or BRAF mutant/ TP53 wild-type advanced CRC patients received oral trametinib once daily and oral HDM201 on days 1 and 8 of a 28-day cycle. The primary endpoint was the maximum tolerated dose (MTD), estimated using the time-to-event Continual Reassessment Method (TITE-CRM). From December 2018 to February 2023, 11 patients received the experimental treatment. The study was prematurely discontinued in July 2023 due to slow accrual. Five (45%) patients experienced grade 3 treatment-related AEs (TRAE). Most common TRAEs were dermatitis acneiform ( n = 9, 82%), diarrhea ( n = 8, 73%), and fatigue ( n = 7, 64%). No objective responses were reported. The safety profile of the combination was consistent with the known safety profile of each drug. The small sample size and early study discontinuation prevent any definitive conclusions. NCT03714958.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-12
DOI
https://doi.org/10.1186/s12885-026-17272-9
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A phase I study of the MEK inhibitor trametinib combined with the MDM2 inhibitor HDM201 in RAS/RAF mutant advanced colorectal cancer

Brunhilde Hanvic, Hélène Vanacker, Philippe Alexandre Cassier, Claire Cropet et al.
BMC Cancer
Colorectal Cancer Treatments and Studies
article

A phase I study of the MEK inhibitor trametinib combined with the MDM2 inhibitor HDM201 in RAS/RAF mutant advanced colorectal cancer

Brunhilde Hanvic, Hélène Vanacker, Philippe Alexandre Cassier, Claire Cropet, Armelle Vinceneux, C. Terret, Mehdi Brahmi, Loïc Verlingue, Gwenaële Garin, Lauriane Eberst, Valery Attignon, Mathilde Troccaz
article en

Abstract

RAS/RAF mutant advanced colorectal cancer (CRC) is associated with poor outcomes and limited therapeutic options. Preclinical studies suggest that combining MEK and MDM2 inhibition may yield synergistic effects. This dose-escalation, phase I study evaluated the safety of escalating doses of the MDM2 inhibitor HDM201 combined with the MEK inhibitor trametinib at a fixed dose. KRAS or BRAF mutant/ TP53 wild-type advanced CRC patients received oral trametinib once daily and oral HDM201 on days 1 and 8 of a 28-day cycle. The primary endpoint was the maximum tolerated dose (MTD), estimated using the time-to-event Continual Reassessment Method (TITE-CRM). From December 2018 to February 2023, 11 patients received the experimental treatment. The study was prematurely discontinued in July 2023 due to slow accrual. Five (45%) patients experienced grade 3 treatment-related AEs (TRAE). Most common TRAEs were dermatitis acneiform ( n = 9, 82%), diarrhea ( n = 8, 73%), and fatigue ( n = 7, 64%). No objective responses were reported. The safety profile of the combination was consistent with the known safety profile of each drug. The small sample size and early study discontinuation prevent any definitive conclusions. NCT03714958.

BMC Cancer
Institut de Cancérologie Strasbourg (FR), Centre Léon Bérard (FR)
Novartis Pharmaceuticals Corporation
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon